Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 11/20 | 0.69 |
| ▸ | CTSS | P25774 | 3/20 | 0.47 |
| ▸ | CCR1 | P32246 | 2/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | CTSV | O60911 | 2/20 | 0.39 |
| ▸ | CTSL | P07711 | 2/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.38 |
| ▸ | CCKBR | P32239 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4218903 | 0.93 | CTSK (0.80) | CTSKCTSSCCR1CTSVCTSL | |
| SCHEMBL4043715 | 0.93 | CTSK (0.80) | CTSKCTSSCCR1CTSVCTSL | |
| SCHEMBL5942432 | 0.93 | CTSK (0.80) | CTSKCTSSCCR1CTSVCTSL | |
| SCHEMBL4039756 | 0.90 | CTSK (0.84) | CTSKCTSSCCR1CNR2CTSV | |
| SCHEMBL4050308 | 0.89 | CTSK (0.65) | CTSKCTSSCCR1CNR2CTSV | |
| SCHEMBL4048208 | 0.89 | CTSK (0.66) | CTSKCTSSCCR1CTSVCTSL | |
| SCHEMBL8349501 | 0.89 | CTSK (0.80) | CTSKCTSSCCR1CTSVCTSL | |
| SCHEMBL4048023 | 0.89 | CTSK (0.80) | CTSKCTSSCCR1CTSVCTSL | |
| SCHEMBL4217341 | 0.89 | CTSK (0.80) | CTSKCTSSCCR1CTSVCTSL | |
| SCHEMBL4041193 | 0.88 | CTSK (0.68) | CTSKCTSSCCR1CNR2CTSV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | claimed |
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | claimed |
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | disclosed |
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | disclosed |
| EP-1546150-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | Amura Therapeutics Limited (GB) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004007501-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | AMURA THERAPEUTICS LIMITED (GB) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100431-A1 | Biologically active compounds | SOST, CTSK, CTSS | CTSK 2/4885CTSS 3/4885CCR1 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.